search
Back to results

Psychoeducation for Patients With Bipolar Disorder in Rwanda

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Not Applicable
Locations
Rwanda
Study Type
Interventional
Intervention
Groups Psychoeducation
Waiting-list
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A diagnosis of BD type I or II that meets DSM-V diagnostic criteria given by a trained psychiatrist
  • No episode in the preceding 4 weeks. Age ≥ 18 years.

Exclusion Criteria:

  • Previous participation in any structured psychological intervention
  • Insufficient understanding of Kinyarwanda
  • Clinical evidence of substantial cognitive impairments.
  • Alcohol or drug-dependence

Sites / Locations

  • Ndera Hospital
  • The University Teaching Hospital of Kigali (CHUK)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Intervention - Psychoeducation at the referral hospital

Waiting list - at the referral hospital

Arm Description

Intervention: Manual-structured group psychoeducation.

Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.

Outcomes

Primary Outcome Measures

Number of patients that relapse
Relapse is defined as a new mood episode of mania (scores above or equal to 20 on the Young Mania Rating Scale (YMRS)(25)), hypomania (above or equal to 12 on the YMRS), or depression (above or equal to 17 on the Hamilton Depression Scale- 17(HDRS-17(26)) or mixed episode (above or equal to 20 on the YMRS and 12 on the HDRS- 17).

Secondary Outcome Measures

Number of patient reporting improvement in medical adherence
Medication Adherence Rating Scale (MARS) will be used to assess beliefs and barriers to medication adherence. Total scores on the MARS may range between 0 and 10, with a higher score indicating better medication adherence.
Number of patient reporting reduction in self-stigma
Internalized Stigma of Mental Illness Inventory - 9-item Version (ISMI-9) will be used to assess self-stigma. The resulting score should range from 1 to 4. A score ranging between 1.00-2.50: does not report high internalized stigma vs. a score ranging between 2.51-4.00: indicating high internalized stigma
Improvement of illness severity
The Clinical Global Impression (CGI-I /CGI-S) will be used for the clinicians to assess how much the participant's condition has improved. The first scale: CGI-Severity (CGI-S) rates illness severity at baseline. The score range between 1 and 7with a higher score indicating serve illness. The other scale CGI-Improvement (CGI-I) tracks improvement after initiation of treatment on a scale from 1 to 7. Four indicates no change. A low score indicates improvement and a high score of worsening symptoms.
Acceptability of the intervention
A seven-item questionnaire based on The theoretical framework of acceptability will be used to access the acceptability of the intervention.

Full Information

First Posted
November 24, 2020
Last Updated
May 24, 2023
Sponsor
University of Aarhus
Collaborators
University of Rwanda, Mental Health Centre Copenhagen
search

1. Study Identification

Unique Protocol Identification Number
NCT04671225
Brief Title
Psychoeducation for Patients With Bipolar Disorder in Rwanda
Official Title
Psychoeducation for Patients With Bipolar Disorder in Rwanda
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
January 15, 2021 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
University of Rwanda, Mental Health Centre Copenhagen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Mental health- and neurological disorders constitute 13% of the global burden of disease. Alarmingly this burden has risen by 41% in the last 20 years. In low-and-middle-income countries as few as 10% of people living with bipolar disorder receive care. In western countries, the efficacy of psychoeducation, as an add-on treatment to pharmacotherapy in the treatment of symptoms and in relapse prevention initiatives with respect to bipolar disorder, is well documented. Yet, few studies on psychosocial interventions for bipolar disorder have been conducted in a low-income country. Aim: To determine the effect, feasibility and acceptability of psychoeducation for patients with bipolar disorder on all three levels of the health care system in Rwanda - at the community health centre, district- and university hospital. Methods: Patients will be randomized into either group A) group-psychoeducation at a referral hospital; or B) group-psychoeducation for both patients and relatives or C) waiting list. Moreover a district trial will test the impact and feasibility of psychoeducation at the district level. Outcomes: Reduction in symptom severity and incidence of relapse, improved quality of life, medical adherence and knowledge, as well as reduced self-stigmatization. Perspectives: If proven successful, this is of importance for closing the huge treatment gap in mental health particularly affecting low- and middle-income countries and may reduce the mortality and increase quality of life in the population suffering from bipolar disorder. Furthermore, potential positive outcomes may be implemented in similar low-resource settings elsewhere.
Detailed Description
Background: Mental health and neurological disorders constitute 13% of the global burden of diseases. Alarmingly this burden has risen by 41% in the last 20 years. It is estimated that severe mental disorders (i.e. severe depression, bipolar disorder, schizophrenia and other psychotic disorders) have a two to three times higher average mortality compared to the general population. Treatment rates for these disorders are low in low-and-middle-income countries (LMICs), where treatment gaps of more than 90% have been documented. In western countries, the efficacy of psychoeducation, as an add-on treatment to pharmacotherapy in the treatment of symptoms and relapse prevention initiatives concerning bipolar disorder (BD), is well documented. Yet, few studies on psychosocial interventions for BD have been conducted in low-income countries. The overall aim of the study is to determine the effect, feasibility and acceptability of psychoeducation for patients with BD in Rwanda. Methods: The study is divided into a prospective randomized controlled trial (RCT) and a district trial. Patients with bipolar disease type I or II that meet DSM-V diagnostic criteria given by a trained psychiatrist and age ≥ 18 years will be invited to participate. For the RCT study participants will be randomised to 1) group-psychoeducation for patients and relatives, 2) a waiting list. The RCT will take place at a referral hospital. The district trial compares the impact of psychoeducation given at the district level by mental health nurses with psychoeducation conducted at referral hospitals. Intervention: Manual-structured group psychoeducation with eight sessions of 90 minutes over eight weeks (at one session per week). Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives. Outcomes: The primary outcome is a reduction in symptom severity, the incidence of relapse and hospitalization. Secondary outcomes include Improved quality of life and medication adherence and knowledge, as well as reduced self-stigmatization. All outcomes will be assessed at baseline, immediately post-intervention, and at the 3 and 6 months follow-up. Sample size: In the literature on group-psychoeducation, 13 out of 18 RCT's have a reduction in general psychiatric symptom severity, the incidence of relapse and hospitalization as main outcomes. Eighteen RCT's on group psychoeducation for BD were reviewed before a study of Colom et al. was selected as the base of the power calculation. The incidence of relapse in the study was (92%) (55 subjects) in the control group vs 67% (40 subjects) in the psychoeducation group. For this study, a sample size of 40 patients for each arm is required to achieve a level of 80% power with a 5% level of significance when comparing the mean change in each intervention with the control arm via a two-sample t-test. Adjusting for a drop-out rate of 20%: 40/(1-(20/100))= 50 participants will be needed for each group (50 for intervention, 50 for waiting-list and 50 for the district trial). Randomization: Study participants at the hospital level who meet the inclusion criteria and sign the informed consent form will be randomized individually into either intervention-arm or waiting list through block-randomization with a ratio of 1:1. Patients at the district level will not be randomized since the number of patients with BD at these levels is unknown and can result in the sample size will be too small. Instead, all will be offered participation. Ethical Approval The research protocol and study-related documents have been approved by the College of Medicine and Health Sciences Institutional Review Board, Rwanda and The National Council for Science and Technology (NCST) in Rwanda.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The RCT: Outpatients from the two-referral hospitals in Rwanda will be invited to participate and be allocated to the intervention group or waiting list. The district trial: This trial compares the impact of the intervention given at the district level with the intervention conducted at the referral hospital. Randomization: Study participants at the hospital level who meet the inclusion criteria and sign the informed consent form will be randomized individually into either intervention-arm or waiting list through block-randomization with a ratio of 1:1. Patients at the district level will not be randomized since we are unsure of the number of patients with Bipolar Disorder at these levels fearing that the sample size will be too small. Instead, all will be offered participation.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
154 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention - Psychoeducation at the referral hospital
Arm Type
Experimental
Arm Description
Intervention: Manual-structured group psychoeducation.
Arm Title
Waiting list - at the referral hospital
Arm Type
Other
Arm Description
Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
Intervention Type
Behavioral
Intervention Name(s)
Groups Psychoeducation
Intervention Description
Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
Intervention Type
Behavioral
Intervention Name(s)
Waiting-list
Intervention Description
Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
Primary Outcome Measure Information:
Title
Number of patients that relapse
Description
Relapse is defined as a new mood episode of mania (scores above or equal to 20 on the Young Mania Rating Scale (YMRS)(25)), hypomania (above or equal to 12 on the YMRS), or depression (above or equal to 17 on the Hamilton Depression Scale- 17(HDRS-17(26)) or mixed episode (above or equal to 20 on the YMRS and 12 on the HDRS- 17).
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Number of patient reporting improvement in medical adherence
Description
Medication Adherence Rating Scale (MARS) will be used to assess beliefs and barriers to medication adherence. Total scores on the MARS may range between 0 and 10, with a higher score indicating better medication adherence.
Time Frame
1 year
Title
Number of patient reporting reduction in self-stigma
Description
Internalized Stigma of Mental Illness Inventory - 9-item Version (ISMI-9) will be used to assess self-stigma. The resulting score should range from 1 to 4. A score ranging between 1.00-2.50: does not report high internalized stigma vs. a score ranging between 2.51-4.00: indicating high internalized stigma
Time Frame
1 year
Title
Improvement of illness severity
Description
The Clinical Global Impression (CGI-I /CGI-S) will be used for the clinicians to assess how much the participant's condition has improved. The first scale: CGI-Severity (CGI-S) rates illness severity at baseline. The score range between 1 and 7with a higher score indicating serve illness. The other scale CGI-Improvement (CGI-I) tracks improvement after initiation of treatment on a scale from 1 to 7. Four indicates no change. A low score indicates improvement and a high score of worsening symptoms.
Time Frame
1 year
Title
Acceptability of the intervention
Description
A seven-item questionnaire based on The theoretical framework of acceptability will be used to access the acceptability of the intervention.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of BD type I or II that meets DSM-V diagnostic criteria given by a trained psychiatrist No episode in the preceding 4 weeks. Age ≥ 18 years. Exclusion Criteria: Previous participation in any structured psychological intervention Insufficient understanding of Kinyarwanda Clinical evidence of substantial cognitive impairments. Alcohol or drug-dependence
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per Kallestrup, Prof.
Organizational Affiliation
University of Aarhus
Official's Role
Study Chair
Facility Information:
Facility Name
Ndera Hospital
City
Kigali
Country
Rwanda
Facility Name
The University Teaching Hospital of Kigali (CHUK)
City
Kigali
Country
Rwanda

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26851330
Citation
Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016 Feb;3(2):171-8. doi: 10.1016/S2215-0366(15)00505-2.
Results Reference
background
PubMed Identifier
25658103
Citation
Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015 Feb 6;10(2):e0116820. doi: 10.1371/journal.pone.0116820. eCollection 2015.
Results Reference
background
PubMed Identifier
26035429
Citation
Gilbert BJ, Patel V, Farmer PE, Lu C. Assessing development assistance for mental health in developing countries: 2007-2013. PLoS Med. 2015 Jun 2;12(6):e1001834. doi: 10.1371/journal.pmed.1001834. eCollection 2015 Jun.
Results Reference
background
PubMed Identifier
28469456
Citation
Rathod S, Pinninti N, Irfan M, Gorczynski P, Rathod P, Gega L, Naeem F. Mental Health Service Provision in Low- and Middle-Income Countries. Health Serv Insights. 2017 Mar 28;10:1178632917694350. doi: 10.1177/1178632917694350. eCollection 2017.
Results Reference
background
Citation
Mackenzie J, Kesner C. Mental health funding and the SDGs What now and who pays ? 2016;(May).
Results Reference
background
PubMed Identifier
19708102
Citation
Kleinman A. Global mental health: a failure of humanity. Lancet. 2009 Aug 22;374(9690):603-4. doi: 10.1016/s0140-6736(09)61510-5. No abstract available.
Results Reference
background
PubMed Identifier
28127922
Citation
Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, Druss B, Dudek K, Freeman M, Fujii C, Gaebel W, Hegerl U, Levav I, Munk Laursen T, Ma H, Maj M, Elena Medina-Mora M, Nordentoft M, Prabhakaran D, Pratt K, Prince M, Rangaswamy T, Shiers D, Susser E, Thornicroft G, Wahlbeck K, Fekadu Wassie A, Whiteford H, Saxena S. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017 Feb;16(1):30-40. doi: 10.1002/wps.20384.
Results Reference
background
PubMed Identifier
15640922
Citation
Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004 Nov;82(11):858-66. Epub 2004 Dec 14.
Results Reference
background
PubMed Identifier
30103990
Citation
Sankoh O, Sevalie S, Weston M. Mental health in Africa. Lancet Glob Health. 2018 Sep;6(9):e954-e955. doi: 10.1016/S2214-109X(18)30303-6. No abstract available.
Results Reference
background
PubMed Identifier
25515608
Citation
Burns JK, Tomita A. Traditional and religious healers in the pathway to care for people with mental disorders in Africa: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2015 Jun;50(6):867-77. doi: 10.1007/s00127-014-0989-7. Epub 2014 Dec 12.
Results Reference
background
PubMed Identifier
28903977
Citation
Keynejad RC, Dua T, Barbui C, Thornicroft G. WHO Mental Health Gap Action Programme (mhGAP) Intervention Guide: a systematic review of evidence from low and middle-income countries. Evid Based Ment Health. 2018 Feb;21(1):30-34. doi: 10.1136/eb-2017-102750. Epub 2017 Sep 13.
Results Reference
background
PubMed Identifier
22335178
Citation
Patel V. Global mental health: from science to action. Harv Rev Psychiatry. 2012 Jan-Feb;20(1):6-12. doi: 10.3109/10673229.2012.649108.
Results Reference
background
PubMed Identifier
24497258
Citation
Colom F. The evolution of psychoeducation for bipolar disorder: from lithium clinics to integrative psychoeducation. World Psychiatry. 2014 Feb;13(1):90-2. doi: 10.1002/wps.20091. No abstract available.
Results Reference
background
PubMed Identifier
29727072
Citation
Soo SA, Zhang ZW, Khong SJ, Low JEW, Thambyrajah VS, Alhabsyi SHBT, Chew QH, Sum MY, Sengupta S, Vieta E, McIntyre RS, Sim K. Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder: A Systematic Review. J Clin Psychiatry. 2018 May/Jun;79(3):17r11750. doi: 10.4088/JCP.17r11750.
Results Reference
background
PubMed Identifier
30202599
Citation
Demissie M, Hanlon C, Birhane R, Ng L, Medhin G, Fekadu A. Psychological interventions for bipolar disorder in low- and middle-income countries: systematic review. BJPsych Open. 2018 Aug 30;4(5):375-384. doi: 10.1192/bjo.2018.46. eCollection 2018 Sep.
Results Reference
background
PubMed Identifier
21975136
Citation
Aubry JM, Charmillot A, Aillon N, Bourgeois P, Mertel S, Nerfin F, Romailler G, Stauffer MJ, Gex-Fabry M, de Andres RD. Long-term impact of the life goals group therapy program for bipolar patients. J Affect Disord. 2012 Feb;136(3):889-94. doi: 10.1016/j.jad.2011.09.013. Epub 2011 Oct 5.
Results Reference
background
PubMed Identifier
15842025
Citation
Simon GE, Ludman EJ, Unutzer J, Bauer MS, Operskalski B, Rutter C. Randomized trial of a population-based care program for people with bipolar disorder. Psychol Med. 2005 Jan;35(1):13-24. doi: 10.1017/s0033291704002624.
Results Reference
background
PubMed Identifier
16816276
Citation
Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M; Cooperative Studies Program 430 Study Team. Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv. 2006 Jul;57(7):927-36. doi: 10.1176/ps.2006.57.7.927.
Results Reference
background
PubMed Identifier
9881538
Citation
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57.
Results Reference
background
PubMed Identifier
728692
Citation
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35. doi: 10.1192/bjp.133.5.429.
Results Reference
background
PubMed Identifier
6080235
Citation
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. doi: 10.1111/j.2044-8260.1967.tb00530.x. No abstract available.
Results Reference
background
PubMed Identifier
28126032
Citation
Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017 Jan 26;17(1):88. doi: 10.1186/s12913-017-2031-8.
Results Reference
background
PubMed Identifier
22008429
Citation
Eaton J, McCay L, Semrau M, Chatterjee S, Baingana F, Araya R, Ntulo C, Thornicroft G, Saxena S. Scale up of services for mental health in low-income and middle-income countries. Lancet. 2011 Oct 29;378(9802):1592-603. doi: 10.1016/S0140-6736(11)60891-X. Epub 2011 Oct 16.
Results Reference
background
PubMed Identifier
12695318
Citation
Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003 Apr;60(4):402-7. doi: 10.1001/archpsyc.60.4.402.
Results Reference
background
PubMed Identifier
26808804
Citation
Schriver M, Cubaka VK, Kyamanywa P, Cotton P, Kallestrup P. Twinning Ph.D. students from south and north: towards equity in collaborative research. Educ Prim Care. 2015 Sep;26(5):349-52. doi: 10.1080/14739879.2015.1079970. Epub 2015 Sep 21. No abstract available.
Results Reference
background
Links:
URL
https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
Description
WHO. Global Health Estimates 2016: Burden of disease by cause, age, sex, by country and by region, 2000-2016. 2018.

Learn more about this trial

Psychoeducation for Patients With Bipolar Disorder in Rwanda

We'll reach out to this number within 24 hrs